First published 9/28/2026, 7:59:15 AM · Last updated 9/28/2026, 7:59:15 AM

Impact of dihydropyrimidine dehydrogenase deficiency on oxidative stress index induced by 5-fluorouracil therapy in patients with stage-III colorectal cancer patients

Aga Khan University Hospital–published journal article examines how dihydropyrimidine dehydrogenase (DPD) deficiency relates to oxidative stress indices in stage-III colorectal cancer patients treated with 5‑fluorouracil. The provided excerpt includes no methodological details or results beyond the article metadata and publication date (2026-09-07).

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study focuses on chemotherapy-associated oxidative stress in a defined patient group, which is relevant to clinical and biomedical research on colorectal cancer.

Sources

Impact of dihydropyrimidine dehydrogenase deficiency on oxidative stress index induced by 5-fluorouracil therapy in patients with stage-III colorectal cancer patients

Report an issue